Alcon Launches UNITY M Ophthalmic Microscope for Enhanced Surgical Precision
Geneva, Switzerland — September 2026 Alcon announced the commercial launch of UNITY® M, a premium ophthalmic surgical microscope designed...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Geneva, Switzerland — September 2026 Alcon announced the commercial launch of UNITY® M, a premium ophthalmic surgical microscope designed...
Cambridge, Massachusetts — September 3, 2026 eGenesis announced an important clinical update from its ongoing Expanded Access study of...
NASHVILLE, Tennessee, August 10, 2026 Insight Molecular Diagnostics, Inc. (iMDx) reported second-quarter 2026 results and provided an update on...
WATERTOWN, Mass., August 6, 2026 LifeMine Therapeutics has secured $263 million in financing to accelerate the clinical development of...
PARIS, France & SCHLIEREN/ZURICH, Switzerland, July 1, 2026 Ipsen has announced a definitive agreement to acquire Memo Therapeutics AG,...
FRANKLIN, Tenn., June 24, 2026 Verici Dx plc announced that it has received clinical laboratory accreditation from the New...
BRISBANE, Calif. | June 16, 2026 CareDx, Inc. has announced the publication of the second analysis from the Kidney...
NASHVILLE, Tenn., June 11, 2026 Insight Molecular Diagnostics, Inc. (Nasdaq: IMDX) announced that the American Journal of Transplantation has...
SCHLIEREN / ZURICH, Switzerland, June 5, 2026 Memo Therapeutics AG announced additional positive analyses from its Phase II SAFE...
COPENHAGEN, Denmark — May 28, 2026 Synklino A/S announced that the first patient has been dosed in a first-in-human...
